HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments.
“We are pleased to fulfill this need and offer customers access to Bio-Rad’s quality control products and solutions for many Abbott clinical diagnostics platforms,” said John Hertia, Bio-Rad President, Clinical Diagnostics Group. “Bio-Rad’s comprehensive suite of quality controls and data management solutions combined with our customer training and support services help to strengthen the performance of clinical labs, ensuring that the most reliable data is provided to physicians and, most importantly, to the patient.”
Bio-Rad is a global leader of quality control products, offering an extensive range of quality controls covering analytes for immunoassay, chemistry, cardiac assessment, immunology, diabetes, coagulation, hematology, blood gas, drugs-of-abuse, and infectious disease testing. The company’s QC data management solutions connect large peer groups of test systems and assay methods to the company’s Unity Interlaboratory Program, enabling labs to compare their results in real time with over 25,000 other labs worldwide.
For further information, please visit http://www.qcnet.com/partners.
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “will”, “believe,” “expect,” “anticipate,” “may,” “plan,” “intend,” “estimate,” “offers,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.